Podcasts and video interviews with researchers, commentators, and experts in the field

Pulling Back the Curtain: Brian G. M. Durie, MD

In more from our interview with Dr. Durie, hear more about how interactions with his father’s doctor piqued Dr. Durie’s interest in medicine, and...

pASHions: B.Y.O.B. (Build Your Own Boat) With Joseph H. Antin, MD

In more from our interview with Dr. Antin, he offers two simple rules for starting a new hobby with your spouse, and discusses the...

Pulling Back the Curtain: Gerald A. Soff, MD

Hear more from our interview with Dr. Soff, where he shares more about his career in hematology, his myeloma diagnosis, and why Sergio Giralt, MD, is...

Eytan M. Stein, MD: Enasidenib Shows “Encouraging” Efficacy in IDH2-Mutated AML

Treatment with the IDH2 inhibitor enasidenib was well-tolerated and led to an "impressive" response rate in patients with relapsed/refractory IDH2-mutated acute myeloid leukemia. Dr....

Jae Hong Park, MD: Improving Outcomes, Minimizing Toxicity With CAR T-Cell Therapy in B-Cell...

Dr. Park reviews two studies identifying characteristics that can improve durability of outcome, without increasing toxicity, in patients with B-cell acute lymphocytic leukemia.

Frederick Locke, MD: CAR T-Cell Therapy in Relapsed/Refractory NHL

Based on results of the ZUMA-1 trial, axicabtagene ciloleucel was submitted to the FDA earlier this year for patients with chemotherapy-refractory, aggressive non-Hodgkin lymphomas....

Mathias Rummel, MD, PhD: Bendamustine-Rituximab “StiL” Beats R-CHOP for Indolent Lymphomas

Ten-year results from the randomized, phase III StiL trial show that bendamustine plus rituximab leads to longer progression-free survival than R-CHOP in patients with...

Saar Gill, MD: Combining CAR T-Cell Therapy With Ibrutinib in CLL Patients

Adding ibrutinib to treatment with CAR T-cell therapy was feasible, led to deeper remissions, and reduced the severity of cytokine release syndrome in patients...

Aaron Gerds, MD: Glasdegib and New Directions in Myelofibrosis Treatment

Dr. Gerds discusses results from an ongoing trial of glasdegib, a novel hedgehog inhibitor, in patients with heavily pretreated myelofibrosis and significant disease burden.

Nicholas J. Short, MD: Inotuzumab Plus Lower-Intensity Chemotherapy Safe, Effective in Older Patients with...

Dr. Short shares results from a “proof-of-concept” study of the combination of inotuzumab ozogamicin and mini-hyper-CVD chemotherapy in older patients with newly diagnosed acute...

Current Issue

November 2017, Volume 3, Issue 13

This issue features a behind-the-scenes look at the ASH annual meeting, bringing newly approved gene therapies to patients, and more.